Clinical Trial Update: Open Label, Multicentre Extension Study of Protocol 42603ATT3002 to Evaluate Safety of Prolonged Release OROS Methlyphenidate in Adults With Attention Deficit Hyperactivity Disorder (ADHD) [Phase 3]

View source ↗

Summary

Open-label, multicentre Phase 3 extension study assessing the safety of prolonged-release OROS methylphenidate in adults with attention deficit hyperactivity di…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• CONCERTA (METHYLPHENIDATE HYDROCHLORIDE)

Snippet

Sponsor: Janssen-Cilag International NV | Conditions: Attention Deficit Disorder With Hyperactivity | Phase 3 | Status: COMPLETED | Results posted: 2010-02-23